Clinical Trial Update: Semaglutide to Reduce Atrial Fibrillation Burden [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating semaglutide to reduce atrial fibrillation burden is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Obesity
• Overweight

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: San Francisco Veterans Affairs Medical Center | Conditions: Atrial Fibrillation, Obesity | Phase 4 | Status: SUSPENDED